Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume 14, Issue 12, Pages 1455-1466
Publisher
Informa UK Limited
Online
2022-01-17
DOI
10.1080/17512433.2021.2028619
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
- (2021) Dan Turner et al. GASTROENTEROLOGY
- From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
- (2021) Ajay M Verma et al. Lancet Gastroenterology & Hepatology
- Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases
- (2021) Silje Watterdal Syversen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
- (2021) Etienne Chatelut et al. Pharmacology Research & Perspectives
- Machine Learning as a Novel Method to Support Therapeutic Drug Management and Precision Dosing
- (2021) Teun Gelder et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Personalized Piperacillin Dosing for the Critically Ill: A Retrospective Analysis of Clinical Experience with Dosing Software and Therapeutic Drug Monitoring to Optimize Antimicrobial Dosing
- (2021) Ute Chiriac et al. Antibiotics-Basel
- Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
- (2021) Ekaterina Gibiansky et al. CPT-Pharmacometrics & Systems Pharmacology
- Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
- (2021) Chetan Rathi et al. CPT-Pharmacometrics & Systems Pharmacology
- Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
- (2021) Ruben Faelens et al. Pharmaceutics
- Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies
- (2020) Aude Desnoyer et al. EUROPEAN JOURNAL OF CANCER
- Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
- (2020) Silje W Syversen et al. Trials
- Impact of Inaccurate Documentation of Sampling and Infusion Time in Model-Informed Precision Dosing
- (2020) Dzenefa Alihodzic et al. Frontiers in Pharmacology
- Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients with Crohn's Disease
- (2020) Erwin Dreesen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Baseline Clearance of Infliximab is Associated with Requirement for Colectomy in Patients with Acute Severe Ulcerative Colitis
- (2020) Robert Battat et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications
- (2020) Amina Bensalem et al. CLINICAL PHARMACOKINETICS
- Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?
- (2020) Wannee Kantasiripitak et al. Frontiers in Pharmacology
- Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
- (2020) Lina Keutzer et al. Frontiers in Pharmacology
- Tacrolimus Exposure Prediction Using Machine Learning
- (2020) Jean‐Baptiste Woillard et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues
- (2020) Zhigang Wang et al. CURRENT OPINION IN PHARMACOLOGY
- Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial
- (2020) Anne S. Strik et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Optimising infliximab induction dosing for patients with ulcerative colitis
- (2019) Erwin Dreesen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease
- (2019) Karen van Hoeve et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
- (2019) A Strik et al. Journal of Crohns & Colitis
- Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases
- (2019) Antoine Petitcollin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
- (2019) Maddalena Centanni et al. CLINICAL PHARMACOKINETICS
- Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data
- (2019) João A. Abrantes et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring
- (2019) Amit Assa et al. GASTROENTEROLOGY
- Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review
- (2019) Antoine Petitcollin et al. CLINICAL PHARMACOKINETICS
- Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
- (2019) Nathalie Van den Berghe et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?
- (2019) Severine Vermeire et al. Clinical Gastroenterology and Hepatology
- DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN’S DISEASE BASED ON SERUM LEVELS OF PROTEINS
- (2019) Geert D’Haens et al. GASTROENTEROLOGY
- Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies
- (2018) Karin A van Schie et al. ANNALS OF THE RHEUMATIC DISEASES
- Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient
- (2018) Richard W. Peck Annual Review of Pharmacology and Toxicology
- Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
- (2018) Erwin Dreesen et al. Clinical Gastroenterology and Hepatology
- Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease
- (2018) Anna Juncadella et al. DIGESTIVE DISEASES AND SCIENCES
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
- (2018) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
- (2018) Geert D’Haens et al. GASTROENTEROLOGY
- Modeling Immunization To Infliximab in Children With Crohn’s Disease Using Population Pharmacokinetics: A Pilot Study
- (2018) Antoine Petitcollin et al. INFLAMMATORY BOWEL DISEASES
- Precision dosing in clinical medicine: present and future
- (2018) Thomas M. Polasek et al. Expert Review of Clinical Pharmacology
- Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?
- (2018) Anne S. Strik et al. AAPS Journal
- OUP accepted manuscript
- (2018) Journal of Crohns & Colitis
- Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis
- (2018) Niels Vande Casteele et al. Clinical Gastroenterology and Hepatology
- Crohn's disease
- (2017) Joana Torres et al. LANCET
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
- (2017) Jean-Frederic Colombel et al. LANCET
- Ulcerative colitis
- (2017) Ryan Ungaro et al. LANCET
- An Update on Inflammatory Bowel Disease
- (2017) Tomoko Sairenji et al. PRIMARY CARE
- Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients
- (2016) Marla C. Dubinsky et al. AAPS Journal
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
- (2016) Johannan F. Brandse et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
- (2016) Omoniyi J. Adedokun et al. Journal of Crohns & Colitis
- Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study
- (2016) Mike van der Have et al. Journal of Crohns & Colitis
- Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Emerging biologics in inflammatory bowel disease
- (2016) Heyson Chi-hey Chan et al. JOURNAL OF GASTROENTEROLOGY
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preventing and Managing Toxicities of High-Dose Methotrexate
- (2016) S. C. Howard et al. ONCOLOGIST
- Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
- (2015) M. Rosario et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
- (2015) N. S. Ding et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- C-Reactive Protein, Fecal Calprotectin and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
- (2015) Mahmoud H Mosli et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice
- (2015) Niels Vande Casteele et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Systematic Review of Health-related Quality of Life Measures for Inflammatory Bowel Disease
- (2015) Laith Alrubaiy et al. Journal of Crohns & Colitis
- Quantifying the Effectiveness of Dose Individualization by Simulation for a Drug With Moderate Pharmacokinetic Variability
- (2015) Lia Liefaard et al. THERAPEUTIC DRUG MONITORING
- Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside
- (2014) Diane R. Mould et al. AAPS Journal
- Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
- (2013) Jean–Frédéric Colombel et al. Clinical Gastroenterology and Hepatology
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- Safe and Effective Variability—A Criterion for Dose Individualization
- (2012) Nicholas H.G. Holford et al. THERAPEUTIC DRUG MONITORING
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
- (2011) Adedigbo A. Fasanmade et al. CLINICAL THERAPEUTICS
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now